Dow jumps with upbeat 3M, Caterpillar earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
3M (MMM) PT Raised to $257 at BofA/Merrill Lynch Following 3Q
October 25, 2017 9:34 AM EDTBofA/Merrill Lynch raised its price target on 3M (NYSE: MMM) to $257.00 (from $227.00) while maintaining a Buy rating following the company's 3Q. 3Ms EPS of $2.33 beat the consensus of $2.21. 3M recorded strategic investments of $48mn ($0.06/sh) in 3Q, below estimates of $0.11 but... More
3M (MMM) PT Raised to $209 at RBC Capital Following 3Q Beat
October 25, 2017 7:47 AM EDTRBC Capital raised its price target on 3M (NYSE: MMM) to $209.00 (from $205.00) while maintaining a Sector Perform rating following the company's 3Q release. The company reported a 12c EPS beat in the quarter. 3M achieved flat pricing in 3Q17, quelling some of the... More
Biogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
October 25, 2017 5:56 AM EDTBiogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS). The trial follows the comprehensive review of SYNERGY, a Phase 2 trial, which identified a specific population that may be more likely to respond to treatment.
These data... More
